Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Apr 20, 2011

Premium

Epigenomics announced this week that Noel Doheny will be the new CEO of its US division in Seattle, Wash. Doheny will join the firm in May and report to Geert Nygaard, CEO of Epigenomics AG.

Doheny brings to Epigenomics more than 30 years of diagnostics experience. He has held senior management positions for more than 20 years. Before joining Epigenomics, Doheny was CEO of OpGen from 2008 to 2009. Additionally, he was senior VP of molecular diagnostics at Affymetrix, and VP of pre-analytical solutions at Qiagen.


Atossa Genetics said that Tim Hunkapiller, founder and CSO of Discovery Business Corp., has joined its scientific advisory board.

Hunkapiller is a co-inventor of the Perkin-Elmer/Applied Biosystems DNA sequencer and he has worked as a researcher at the California Institute of Technology and the University of Washington.


Rosetta Genomics has tapped Brian Markison to be its new board chairman. He will replace Yoay Chelouche, who recenlty resigned the post.

Markison formerly was CEO and chairman of King Pharmaceuticals. Chelouche will continue to serve as chairman of Rosetta Green, the firm's majority-held subsidiary.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.